AC Immune SA has announced the appointment of Dr. Günther Staffler as the interim Executive Vice President, Development. Dr. Staffler, who joined the company in 2021, will oversee the development of active immunotherapies and clinical activities. Previously, he held senior roles at Affiris and other biotech companies in Vienna. Concurrently, Dr. Anke Post, the current Chief Medical Officer, will be leaving the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.